Surgical resection of hepatocellular carcinoma

Cancer Journal

Volumn 14, Issue 2, 2008, Pages 100-110

  Duffy, John P ^a   Hiatt, Jonathan R ^a   Busuttil, Ronald W ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Liver resection

Indexed keywords

ALPHA2B INTERFERON; PLACEBO; SORAFENIB;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; GRAFT SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT INDICATION; ALGORITHM; ARTICLE; LIVER TUMOR; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; SURVIVAL;

ALGORITHMS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; SURVIVAL ANALYSIS;

EID: 50549097007     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31816a5c1f     Document Type: Review

References (72)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34.
4. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
5. El Serag HB, Siegel AB, Davila JA. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166.
6. Bruix J, Hessheimer AJ, Forner A, et al. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856.
7. El-Serag HM, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227-3230.
8. Yamamoto J, Iwatsuki S, Kosuge T, Dvorchik I, Shimada K, Marsh JW, Yamasaki S, Starzl TE. Should hepatomas be treated with hepatic resection or transplantation? Cancer. 1999;86:1151-1158.
9. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509.
10. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population based study. Hepatology. 2000;32:842-846.
11. Wong LM, Limm WM, Severino R, et al. Improved survival with screening for hepatocellular carcinoma. Liver Transpl. 2000;6:320-325.
12. Oka H, Kurioka N, Kim K, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990; 12:680-687.
13. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effective analysis. Gut. 2001;48:251-259.
14. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130: 417-422.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
16. Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996;78:977-985.
17. Izuno K, Fujiyama S, Yamasaki K, et al. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-γ-carboxy prothrombin and α-fetoprotein: a prospective study. Hepatogastroenterology. 1995;42:387-393.
18. Liu JH, Chen PW, Asch SM, et al. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol. 2004;11:298-303.
19. Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg. 2003;238:508-518.
20. Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg. 2003;238:885-892.
21. Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 2004;10: 36-41.
22. Lu DSK, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137.
23. Greene FL, Page DL, Fleming ID, et al., eds. ALCC Cancer Staging Manual. 6th ed. Chicago, IL: Springer; Chicago 2002;131-144.
24. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging system for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527-1536.
25. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720-727.
26. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840-845.
27. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology. 2000;31:1019-1021.
28. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760-1769.
29. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 4th ed. Tokyo, Japan; 2000.
30. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207-215.
31. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer. 1985;56:918-928.
32. Sala M, Forner A, Varela M, et al. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis. 2005;25:171-180.
33. Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002;235: 722-730.
34. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
35. Huo T-I, Lui W-Y, Wu J-C, et al. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg. 2004;28:258-262.
36. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322-330.
37. Shoup M, Gonen M, D'Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325-330.
38. Balzan S, Belghiti J, Farges O, et al. The "50-50 Criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824-829.
39. Couinaud C. Le Foie. Etudes Anatomiques et Chirurgicales. Paris, France: Masson; 1979.
40. Cantlie J. On a new arrangement of the right and left lobes of the liver. J Anat. 1897;32:4.
41. Pringle JH. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg. 1908;48:541-549.
42. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically-guided subsegmentectomy. Surg Gynecol Obstet. 1985;161:346-350.
43. Arita J, Kokudo N, Zhang K, et al. Three-dimensional visualization of liver segments on contrast-enhanced intraoperative sonography. AJR Am J Roentgenol. 2007;188:W464-W466.
44. Scudamore CH, Buczkowski AK, Shayan H, et al. Mesohepatectomy. Am J Surg. 2000;179:356-360.
45. Stratopolous C, Soonawalla Z, Brockmann J, et al. Central hepatectomy: the golden mean for treating central hepatic tumors? Surg Oncol. 2007;16:99-106.
46. Gruttadauria S, Marsh W, Bartlett DL, et al. Ex situ resection techniques and liver autotransplantation: last resource for otherwise unresectable malignancy. Dig Dis Sci. 2005;50:1829-1835.
47. Hemming AW, Reed AI, Langham MR, et al. Combined resection of the liver and inferior vena cava for hepatic malignancy. Ann Surg. 2004; 239:712-719.
48. Raab R, Schlitt HJ, Oldhafer KJ, et al. Ex-vivo techniques in tissue preserving surgery for liver malignancies. Langenbeck's Arch Surg. 2000;385:179-184.
49. Kokudo N, Sugawara Y, Imamura H, et al. Sling suspension of the liver in donor operation: a gradual tape-repositioning technique. Transplantation. 2003;76:803-807.
50. Belghiti J, Noun R, Malafosse R, et al. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg. 1999;229:369-375.
51. Koffron AJ, Auffenburg G, Kung R, et al. Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg. 2007;246:385-392.
52. Belghiti J, Hiramatsu J, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38-46.
53. Jarnagin W, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397-406.
54. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240:698-708.
55. Otsuka Y, Duffy JP, Saab S, et al. Postresection hepatic failure: successful treatment with liver transplantation. Liver Transpl. 2007;13:672-679.
56. Song T-J, Ip EWT, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology. 2004;127:S248-S260.
57. Cha CH, Ruo L, Fong Y, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238:315-321.
58. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without portal vein embolization. Arch Surg. 2002;137:675-680.
59. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686-691.
60. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237: 208-217.
61. Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg. 2006;93:1091-1098.
62. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment of early hepatocellular carcinoma: resection versus transplantation. Hepatology. 2000;32:1434-1440.
63. Belghiti J, Regimbeau JM, Durand F, et al. Resection of hepatocellular carcinoma: a European experience on 328 cases. Hepatogastroenterology. 2002;49:41-46.
64. Taura K, Ikai I, Hatano E, et al. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery. 2007; 142:685-694.
65. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245:831-842.
66. Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922.
67. Lubrano J, Huet E, Tsilividis B, et al. Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse. World J Surg. 2008;32:104-109.
68. Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216-222.
69. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000:89:500-507.
70. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373-382.
71. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122-130.
72. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 2008;112:250-259.